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ORIGINAL ARTICLE
Astrocyte senescence may drive alterations in GFAPα,
CDKN2A p14ARF, and TAU3 transcript expression
and contribute to cognitive decline
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Abstract The accumulation of senescent cells in tissues
is causally linked to the development of several age-
related diseases; the removal of senescent glial cells in
animal models prevents Tau accumulation and cognitive
decline. Senescent cells can arise through several dis-
tinct mechanisms; one such mechanism is dysregulation
of alternative splicing. In this study, we characterised the
senescent cell phenotype in primary human astrocytes in
terms of SA-β-Gal staining and SASP secretion, and
then assessed splicing factor expression and candidate
gene splicing patterns. Finally, we assessed associations
between expression of dysregulated isoforms and pre-
mature cognitive decline in 197 samples from the
InCHIANTI study of ageing, where expression was
present in both blood and brain. We demonstrate here
that senescent astrocytes secrete a modified SASP
characterised by increased IL8, MMP3, MMP10, and
TIMP2 but decreased IL10 levels. We identified signif-
icant changes in splicing factor expression for 10/20
splicing factors tested in senescent astrocytes compared
with early passage cells, as well as dysregulation of
isoform levels for 8/13 brain or senescence genes tested.
Finally, associations were identified between peripheral
blood GFAPα, TAU3, and CDKN2A (P14ARF) isoform
levels and mild or severe cognitive decline over a 3–7-
year period. Our data are suggestive that some of the
features of cognitive decline may arise from dysregulat-
ed splicing of important genes in senescent brain sup-
port cells, and that defects in alternative splicing or
splicing regulator expression deserve exploration as
points of therapeutic intervention in the future.
Keywords Neurodegenerative disease . Alternative
splicing . Senescence . Gene expression
Introduction
Age is a major risk factor for cognitive decline and
neurodegenerative disease, as it is for most common,
chronic disorders (Niccoli and Partridge, 2012). The
accumulation of senescent cells in tissues and organs
has emerged as a major driver of the ageing process and
age-related disease in mammals; selective removal of
such cells in genetically engineered animals has been
demonstrated to reverse or delay aspects of ageing
(Baker et al., 2016, Baker et al., 2011). Senescent cells
are alive and metabolically active, but have altered
function compared with their non-senescent
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counterparts. A major feature of senescence is secretion
of the senescence-associated secretory phenotype
(SASP) which can act in a paracrine manner on
neighbouring cells to drive organismal ageing (Freund
et al., 2010). Although terminally differentiated cells
such as neurones may not undergo replicative senes-
cence in the accepted sense, other important support
cells in the brain such as astrocytes that do have prolif-
erative capacity are subject to this phenomenon. Astro-
cytes have a pivotal role in maintenance of trophic
factors, neurotransmitters, and the support and strength-
ening of neuronal connections (Sidoryk-Wegrzynowicz
et al., 2011). Previous evidence has suggested that the
accumulation of senescent astrocytes may drive neuro-
degenerative disorders (Di Malta et al., 2012) and recent
work shows that clearance of senescent glial cells may
prevent the accumulation of Tau aggregates and im-
prove cognitive function in mouse models (Bussian
et al., 2018, Baker and Petersen, 2018). Pharmacologi-
cal impairment of astrocytic function recapitulates cog-
nitive deficits that are observed in old age (Tarantini
et al., 2017). It is also noteworthy that irradiation-
induced accumulation of senescent cells is associated
with cerebromicrovascular dysfunction in animal
models (Ungvari et al., 2017).
Cells enter a senescent state for a number of reasons,
one of which is repeated exposure to internal and exter-
nal stressors (de Magalhaes and Passos, 2018). Expo-
sure to cellular stress elicits an adaptive and plastic
transcriptional response, which is partly orchestrated
by alternative splicing (Mastrangelo et al., 2012). Alter-
native splicing is mediated by the combinatorial binding
of a series of splicing activators and inhibitors to splic-
ing enhancer and silencer sequences around the splice
sites to determine whether or not each splice site is used
(Fu and Ares, 2014, Smith and Valcarcel, 2000).
Supporting the notion of a pivotal role for dysregulated
alternative splicing in senescence, transcripts associated
with chronological age in humans are enriched in gene
ontology pathways involved in splice site choice
(Harries et al., 2011) and splicing factor expression is
also associated with cellular senescence in in vitro
models (Holly et al., 2013), with human ageing pheno-
types (Lee et al., 2019) and with lifespan in long-lived
mice (Lee et al., 2016). Perhaps most persuasively,
restoration of splicing factor levels is associated with
rescue of cellular senescence in multiple human primary
human cell types (Latorre et al., 2017, Latorre et al.,
2018a, Latorre et al., 2018c). Changes to the regulation
of splicing have previously been reported in
Alzheimer’s Disease (Wong, 2013) and global dysreg-
ulation of splicing is a characteristic of several neurode-
generative conditions such as Huntington’s disease (Lin
et al., 2016), frontotemporal lobar dementia (Gao et al.,
2017), and Parkinson’s Disease (Soreq et al., 2012).
Specially, alterations to the splicing pattern of theMAPT
genewhich encodes Tau protein are known to contribute
to neurofibrillary tangles (Goedert and Jakes, 1990).
We hypothesised that senescent astrocytes would
display differential expression of splicing regulatory
factors and altered patterns of alternative splicing
in vitro, and that some of these isoform changes may
be detectable in peripheral blood and show statistical
associations with cognitive phenotypes in human popu-
lations. We first characterised the astrocyte SASP in
terms of cytokine and MMP production, and then deter-
mined the splicing factor repertoire and patterns of
alternative splicing for a panel of brain or senescence
candidate genes in senescent human primary astrocytes.
Where dysregulation of splicing patterns was demon-
strated and expression was conserved in blood, we then
assessed associations between peripheral blood isoform
levels and measures of cognitive dysfunction from 197
individuals from the InCHIANTI study of ageing, a
longitudinal and cross-sectional population study of
individuals from the Tuscany region of Italy (Ferrucci
et al., 2000). We identified that senescent astrocytes
display a modified SASP, consisting of elevated IL8,
MMP, MMP10, and TIMP2 levels, but decreased IL10.
Of the splicing regulatory factors tested, 50% demon-
strated dysregulated expression in senescent astrocytes;
this was accompanied by altered splicing of 7/13 of
candidate genes tested. Furthermore, when we assessed
the relationship between peripheral blood expression of
isoforms dysregulated in astrocytes and cognitive de-
cline as measured my Mini Mental State Exam
(MMSE), GFAPα and TAU3 transcript levels were pos-
itively correlated with cognitive decline, whereas
GFAPΑ transcript levels were negatively associated
with cognitive decline over a 3–7-year period in partic-
ipants from the InCHIANTI study of ageing. Our data
are in agreement with the hypothesis that senescent
astrocytes display differential expression of splicing
regulatory factors and altered patterns of alternative
splicing, and that some of these isoform changes may
reflect those in peripheral blood. Such changes may
show statistical associations with cognitive phenotypes
in human populations.
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Experimental protocols
Culture of early and senescent astrocytes
These studies used cultures of early passage and late
passage human primary astrocytes (HPA) previously
isolated from a block of sub-ventricular deep white
matter tissue in a 17-year-old male donor immediately
post-mortem with consent from next-of-kin. Ethical ap-
proval was granted by the North and East Devon Re-
search Ethics Committee. Astrocytes were isolated from
tissue blocks as previously described (Holley et al.,
2005). Cells were maintained in humidified incubators
with 95% O2/5% CO2 in HPA stock media (Celprogen
Inc., Torrance, CA, USA). For the production of senes-
cent cultures, cells were counted and equal numbers of
cells seeded (4 × 103 cell/cm2) at each passage in con-
tinuous culture until the growth of the culture slowed to
less than 0.5 population doublings (PD)/week. Astro-
cyte cultures underwent continuous culture until the
onset of replicative senescence and growth arrest in 3
biological replicates. Early passage astrocytes at PD =
24 and late passage astrocytes at PD = 84 were used.
Quantification of senescent cell load
Cell senescence was assessed in 3 biological replicates
by the biochemical senescence marker senescence-
associatedβ-galactosidase (SA-β-Gal) using a commer-
cial kit (Sigma Aldrich, UK) according to the manufac-
turer’s instructions, with a minimum of 100 cells
assessed per replicate. Senescence was also quantified
by assessing the expression of the CDKN2A gene (a
known molecular marker of cell senescence) and by
changes in cell morphology typical of senescence as in
our previous work (Latorre et al., 2017, Holly et al.,
2013). Total RNA (100 ng) was reverse transcribed in
20 μl reactions using EvoScript reverse transcriptase
(Roche Life Sciences, Burgess Hill, UK). Total
CDKN2A expression was measured by qRT-PCR rela-
tive to 3 empirically determined endogenous control
genes (GUSB, PPIA, and GADPH) on the QuantStudio
12K Flex platform (Applied Biosystems, Foster City,
USA). PCR reactions contained 2.5 μl TaqMan Univer-
sal Mastermix (no AMPerase) (Applied Biosystems,
Foster City, USA), 900 nM of each primer, 250 nM
probe, and 0.5 μl cDNA in a total volume of 5 μl.
Cycling conditions were a single cycle of 95 °C for
10 min followed by 40 cycles of 95 °C for 15 s and
60 °C for 1 min.
Characterisation of the senescence-associated secretory
phenotype in early and late passage cells
Cells were seeded in two biological replicates of 10 ×
104 cells in a 25-cm2 flasks and cultured until 80%
confluence. Cell supernatants were then harvested and
stored at − 80 °C. The senescence-associated secretory
phenotype was then quantified in the culture media
following 48 h incubation using the ABCAM Human
Cytokine Antibody Array (ab133997; Abcam, Cam-
bridge, UK) and the ABCAM Human MMP Antibody
Array (ab134004; Abcam, Cambridge, UK). SASP
components measured were as follows: IL-1B, IL-2,
Il-6, IL-8, IL-10, TNF-α, IFN-γ, GM-CSF, Angiogenin,
ENA78, GRO-α, MMP3,MMP10, and TIMP2. Results
were normalised using positive and negative controls as
per the kit instructions using the LI-COR Odyssey®
CLx imaging system (Lincoln, NE, USA). An unpaired
two tailed t test was used to assess statistical significance
in secreted matrix metalloproteinases and inflammatory
cytokine secretion using Minitab 18 software package
(Minitab, Centre County, USA).
Quantification of splicing factor expression
Splicing factors have previously been demonstrated to
be associated with cellular senescence with evidence
suggesting they may be drivers of this process in some
tissues (Latorre et al., 2017, Latorre et al., 2018a,
Latorre et al., 2018c). We measured the expression
levels of an a priori panel of 20 splicing factors previ-
ously associated with age, lifespan, and cellular senes-
cence in different tissue types in our previous work
(Harries et al., 2011, Holly et al., 2013, Latorre et al.,
2018b). This panel included the splicing inhibitors
HNRNPA0, HNRNPA1, HNRNPA2B1, HNRNPD,
HNRNPH3, HNRNPK, HNRNPM, HNRNPUL2, the
splicing activators AKAP17A, PNISR, SRSF1, SRSF2,
SRSF3, SRSF6, TRA2B, SRSF7 and the SF3B1, IMP3,
LSM14A , and LSM2 components of the core
spliceosome. Splicing factor expression was measured
in 3 biological and 2 technical replicates by qRT-PCR
using custom TaqMan Low Density Arrays (TLDA) on
the Quantstudio 12K Flex platform as previously de-
scribed (Holly et al., 2013). Transcript levels were
expressed relative to the geometric mean of the GUSB
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and PPIA endogenous control genes and normalised to
their expression in RNA from early passage cells. We
then performed tests for equality of variance and t test
using IBM SPSS Statistics 25.
Quantification of candidate gene expression in early
passage and senescent astrocytes
A panel of candidate genes were selected for analysis on
the basis of biological relevance (known links with brain
function, neurodegenerative disease, or senescence) and
where available evidence from the literature that alter-
natively expressed isoforms may have differential func-
tion to allow interpretation of changes. The identity of
genes tested and the rationale for their inclusion are
given in Table 1. TaqMan Assays specific to particular
isoforms were designed to unique regions of the tran-
scripts in question (assay sequences are available upon
request). Assays were validated by standard curve anal-
ysis using 7 serial 1:2 dilutions of cDNA derived from
the whole brain lysate. Reverse transcription and qRT-
PCR conditions are described above. Experiments were
carried out in 3 biological and 3 technical replicates.
Transcript levels were expressed relative to GUSB and
PPIA endogenous control genes and normalised to their
expression in RNA from early passage cells. We then
performed tests for equality of variance and t test using
IBM SPSS Statistics 25.
Assessment of candidate gene expression levels
with cognitive decline in a longitudinal human
population
The InCHIANTI study of ageing is a population study
of ageing with detailed assessment of health and life-
style parameters at baseline, and again at 4 subsequent
follow-ups (FU2; 2004–2006, FU3; 2007–2009, and
FU4; 2012–2014) (Ferrucci et al., 2000). We selected
197 participants for study. Inclusion criteria were age at
FU3 > 64 years with an MMSE score > 18 to avoid
those already on a declining cognitive trajectory and
availability of an FU3 RNA sample with clinical infor-
mation available at both FU3 and FU4. Participants
were categorised into ‘mild’ or ‘severe’ groups depend-
ing their change in the MMSE score between FU3 and
FU4; individuals declining between 2 and 8 points were
defined as ‘mild’, whereas those declining between 9
and 22 points were categorised as ‘severe’. These
thresholds were chosen on the basis of previously
defined criteria, where a ‘severe’ decline was
categorised as a drop in MMSE score > 3 points per
annum (Clark et al., 1999, McCarten et al., 2004,
Hensel et al., 2007). Ethical approval was granted by
the Instituto Nazionale Riposo e Cura Anziani institu-
tional review board in Italy. Methods were carried out in
accordance with the relevant guidelines and regulations.
Informed consent was obtained from all participants.
Blood was collected into PAXgene tubes (BD Biosci-
ences) at FU3 and extracted using the PAXgene blood
RNA kit (Qiagen, Paisley, UK). One hundred nanograms
RNA was then reverse transcribed using the EvoScript
Universal cDNA Master kit (Roche Life Sciences, Bur-
gess Hill, UK) according to the manufacturer’s instruc-
tions except for a change to the extension phase of the
reaction: a step of 30 min at 65 °C was used instead of
15 min at 65 °C. Expression levels for transcripts show-
ing senescence-related dysregulation in levels in astro-
cytes were quantified in peripheral blood as described
above. Samples were assessed in 3 technical replicates.
Data were log transformed and multivariate linear regres-
sion models were performed using STATA© SE 15 to
investigate the association between transcript expression
and cognitive decline as measured by change (Δ) in
MMSE score. Models were adjusted for age, gender,
smoking (lifetime pack-years), study site, education level,
and white blood cell subtype counts (% neutrophils,
monocytes, basophils, eosinophils).
Results
Characterisation of senescent astrocytes
Human primary astrocyte cultures were considered se-
nescent at PD84 at which point they were considered
senescent. This was verified by molecular and biochem-
ical characterisation of the growth kinetics of the cul-
tures; senescence-associated β-galactosidase (SA-β-
gal) staining demonstrated a significant increase in the
number of senescent cells from 8% in early passage cells
to 36% in late passage cells (Fig. 1a) which was mir-
rored by a concurrent increase in the expression of the
CDKN2A gene (Fig. 1b). SASP factors in conditioned
media derived from senescent cells demonstrated altered
levels for several key SASP proteins; we observed ele-
vated IL-8, GM-CSF, Angiogenin, ENA78, GRO-α,
MMP-3, MMP-10, and TIMP2 levels, but reduced IL-
10 levels (Table 2).
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Changes in splicing factor expression and patterns
of alternative splicing in senescent astrocytes
We have previously demonstrated changes in splicing
factor expression in senescent primary human cells of
different lineages (Holly et al., 2013, Latorre et al.,
2017, Latorre et al., 2018b, Latorre et al., 2018c). Sim-
ilar changes were also apparent in senescent astrocytes,
where 10/20 of the splicing factors tested demonstrated
lower expression in late passage cells compared with
earlier passage cells (Table 3). Both HNRNP splicing
inhibitors and serine-arginine (SR) rich splicing
Table 1 Transcript isoforms
identified for expression analysis
The table gives the identity of the
isoforms selected for analysis, the
relevant NM accession numbers,
and a brief description of their
function
Gene Transcript accession Isoform/transcript function
ATM NM_000051.3 DNA damage repair
AQP4
AQP4M1 NM_001650.6 Pore-forming integral membrane protein
AQP4M23 NM_004028.4 Pore-forming integral membrane protein
SLC1A2
EAAT2A NM_004171.4 Excitatory amino acid transporter
EAAT2B NM_001252652.1 Excitatory amino acid transporter
GFAP
GFAPΑ NM_002055 Astrocyte intermediate filament protein
GFAP(B) NM_001131019.1 Astrocyte intermediate filament protein
KL
KLOTHO mKl NM_004795 Membrane bound isoform, coreceptor for FGF23
KLOTHO msKl NM_004795.3 Secreted isoform, endocrine factor which
improves cognitive performance in ageing
CDKN2A
p14ARF NM_058195 p53 pathway to cell cycle cessation
p16INK4A NM_001195132 RB1 pathway to cell cycle cessation
(Takahashi et al., 2007)
CDKN1A
p21a NM_078467 Inhibits proliferation
p21b NM_000389 Promotes proliferation
TP53 NM_001126118,
NM_000546,
NM_001126112,
NM_001276696,
NM_001126113,
NM_001276699,
NM_001276698,
NM_001276697
Cell cycle regulation
PSEN2 NM_012486.2 Processing of β-amyloid
MAPT
TAU3 NM_001203251.1
NM_001203252.1
NM_016841.4
Microtubule protein involved in
neurofibrillary tangles
TAU4 NM_001123066.3
NM_001123067.3
NM_005910.5
NM_016834.4
NM_016835.4
Microtubule protein involved in
neurofibrillary tangles
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activator transcripts demonstrated dysregulation; 4/8
(50%) transcripts encoding splicing inhibitors, 3/8 splic-
ing activator transcripts, and 3/4 (75%) of core
spliceosomal transcripts demonstrated changed expres-
sion in senescent astrocytes. Most genes selected for
study were expressed in astrocytes; only AQP4M1,
EAAT2A, and EAAT2Bwere not. Eight of the remaining
13 transcripts demonstrated changes to their splicing
patterns (Table 4).
Association of senescence-related transcripts
with cognitive decline in a longitudinal human
population
We next assessed whether any of the transcripts demon-
strating senescence-related changes in aged primary
human astrocytes were associated with cognitive de-
cline as assessed by change in MMSE score between
FU3 and FU4, in peripheral blood mRNA from individ-
uals in the InCHIANTI study of ageing. Of the 8 tran-
scripts demonstrating associations with senescence in
late passage astrocytes, TAU3, GFAPα, mKLOTHO
CDKN2A ( p 1 4 A R F ) , CDKN2A ( p 1 6 I N K 4 A ) ,
CDKN1A(p21a), CDKN1A(p21b), and PSEN2 were al-
so expressed in peripheral blood, and suitable for ongo-
ing analysis. CDKN2A (p14ARF) and TAU3 were posi-
tively associated with mild cognitive decline (CDKN2A
(p14ARF) beta coefficient 0.122, 95% CI 0.01 to 0.24;
p = 0.04, TAU3 beta coefficient 0.170, 95% CI 0.042 to
0.297; p = 0.01), whereas GFAPα was negatively asso-
ciated with mild cognitive decline (beta coefficient −
0.196 (95%CI− 0.36 to 0.032; p= 0.02; Fig. 2; Table 5).
Fig. 1 Senescent cell quantification in early passage and late
passage human primary astrocytes. a This graph gives the change
in senescent cell load as determined by senescence-associated β-
galactosidase (SA-β-Gal) staining between early passage and late
passage human primary astrocytes. The percentage of cells stain-
ing positive for SA-β-Gal is given on the Yaxis and the identity of
the cell culture on the X axis. b Change in senescent cell load as
determined by CDKN2A expression between early passage and
late passage human primary astrocytes. Levels of CDKN2A tran-
scripts relative to the endogenous control genes (GUSB, PPIA, and
GADPH) and normalised to the expression levels in early passage
cells are given on the Y axis and the identity of the cell culture on
the X axis. Early passage cells are population doubling (PD) 24;
late passage cells are at PD = 84. Results are from 3 biological
replicates. *p < 0.01, **p < 0.01, ***p < 0.001. Error bars refer to
standard deviation of measurement. c Senescence-associated β-
galactosidase staining in early passage astrocytes (PD 24). d
Senescence-associated β-galactosidase staining in late passage
astrocytes (PD 84)
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Interestingly, the only association we found with severe
cognitive decline was a negative association with TAU3
(beta coefficient − 0.286, 95% CI − 0.56 to 0.04; p =
0.04). GFAPα and TAU3 demonstrated significant dif-
ferences in level of isoform expression between mild
and severe cognitive decline (Fig. 2, Table 5).
Discussion
The accumulation of senescent cells as a result of repeated
cell stresses is thought to be a major contributor to ageing
and age-related disease. The ablation of senescent cells is
able to bring about improvements in multiple age-related
phenotypes in animal models (Baker and Petersen, 2018,
Baker et al., 2011). Furthermore, correlations exist between
circulating levels of senescence markers such as p16INK4a
and HMGB2 and functional status in humans (Lawrence
et al., 2018). Suppression of senescent cell characteristics
such as SASP using the flavonoid apigenin has also been
demonstrated to reduce aggressive behaviour in breast
cancer cells, providing further evidence reduction of se-
nescent cell load may bring benefits for age-related dis-
eases (Perrott et al., 2017).
Age-related dysregulation of alternative splicing may
contribute to the accumulation of senescent cells during
ageing. Alternative splicing, a key part of the molecular
stress response that is a critical mediator of cellular
plasticity and adaptability, has been shown to be
disrupted during human ageing; restoration of splicing
factor expression is able to reverse cellular senescence
and bring about rejuvenation of multiple cell types in
culture. We hypothesised that senescent astrocytes
would display differential expression of splicing regula-
tory factors and altered patterns of alternative splicing
in vitro, and that some of these isoform changes may be
detectable in peripheral blood and show statistical asso-
ciations with cognitive phenotypes in human popula-
tions. We demonstrated that 50% of splicing factor
transcripts we measured demonstrated dysregulated ex-
pression in senescent astrocytes, and splicing changes
were evident for almost half of the alternatively spliced
Table 2 Evaluation of astrocyte SASP. Level of secreted cyto-
kines and matrix metalloproteinase proteins in senescent and non-
senescent human primary astrocytes is given below
Cytokine Early passage (SE) Late passage (SE) p value
IL-1B 274.233 (24.37) 286.058 (36.82) 0.798
IL2 74.659 (23.99) 111.541 (18.97) 0.273
IL-6 78.752 (11.81) 73.490 (9.49) 0.740
IL-8 409.541 (55.96) 1097.730 (128.17) 0.003
IL-10 56.560 (9.53) 18.219 (4.79) 0.011
TNF-α 10.214 (6.50) 16.812 (8.12) 0.576
IFN-γ 120.787 (20.05) 137.933 (23.89) 0.602
GM-CSF 27.060 (3.82) 66.130 (7.63) 0.004
Angiogenin 881.4542 (106.96) 1397.6704 (103.33) 0.013
ENA78 160.618 (28.74) 270.255 (27.36) 0.033
GRO-α 256.152 (27.78) 461.5086 (65.09) 0.027
MMP-3 75.897 (7.49) 128.3126 (15.34) 0.022
MMP-10 6.284 (3.15) 18.566 (2.58) 0.023
TIMP-2 4723.167 (190.92) 8402.9399 (505.84) < 0.001
SASP, senescence-associated secretory phenotype. Cytokines
demonstrating significant differences in expression are given in
boldface. Cytokine expression is measured as arbitrary units (AU).
N = 2 biological and 2 technical replicates per sample. SE, stan-
dard error
Table 3 Comparison of splicing factor levels in senescent and
non-senescent astrocytes
Splicing
factor
Early passage
astrocytes
Late passage
astrocytes
p
value
AKAP17A 1.035 (0.090) 1.01 (0.044) 0.077
HNRNPA0 1.024 (0.077) 0.65 (0.031) 0.005
HNRNPA1 1.236 (0.340) 1.863 (0.416) 0.449
HNRNPA2B1 1.343 (0.353) 0.6 (0.108) 0.257
HNRNPD 1.094 (0.180) 0.646 (0.048) 0.03
HNRNPH3 1.071 (0.130) 0.743 (0.037) 0.003
HNRNPK 1.153 (0.176) 1.37 (0.209) 0.551
HNRNPM 1.021 (0.068) 0.66 (0.067) 0.012
HNRNPUL2 1.074 (0.148) 0.784 (0.106) 0.089
IMP3 1.088 (0.160) 0.62 (0.11) 0.035
LSM14A 1.042 (0.113) 0.315 (0.047) 0.005
LSM2 1.377 (0.426) 0.369 (0.045) 0.065
PNISR 1.041 (0.098) 0.777 (0.030) 0.005
SF3B1 1.018 (0.070) 0.716 (0.030) 0.018
SRSF1 1.06 (0.140) 0.885 (0.038) 0.065
SRSF2 1.038 (0.095) 1.017 (0.045) 0.121
SRSF3 1.077 (0.175) 0.697 (0.032) 0.095
SRSF6 1.07 (0.126) 0.762 (0.104) 0.098
TRA2B 1.022 (0.081) 0.757 (0.057) 0.031
SRSF7 1.119 (0.198) 0.51 (0.063) 0.015
Values given refer to the mean expression of each splicing factor in
either early or late passage cells. Values in parentheses are the
standard error of the mean. Splicing factors demonstrating signif-
icant differences in expression are given in boldface. N = 3 bio-
logical and 3 technical replicates per sample
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genes in an a priori panel of candidate genes. Eight of
the 13 candidate isoforms demonstrated splicing alter-
ations in senescent cells, and were also expressed in
human peripheral blood. Of these, 3 (TAU3, GFAPα,
and CDKN2A (p14ARF)) were associated with mild cog-
nitive decline in ageing humans. The TAU3 isoform was
also associated with severe cognitive decline, but in an
opposing direction. Our data are consistent with a mod-
el, whereby age-related splicing factor changesmay lead
to splicing patterns for genes with roles in brain function
or senescence, which may influence the development of
cognitive decline in the human population. The links
between splicing factor changes and isoform changes
are impossible to predict from global measures. Each
individual splice site in each gene is regulated by a
unique and specific combination of activators and in-
hibitors which determine its usage or not, which makes
prediction impossible from levels alone. What our data
do indicate is that senescent astrocytes have disrupted
expression of many splicing factors, which would be
predicted to alter the splicing patterns. We have demon-
strated that this holds true for a number of genes impor-
tant in senescence or in astrocyte function.
Some of the adverse effects of the presence of senes-
cent cells arise because of the paracrine signalling
effects of the SASP on neighbouring cells. The presence
of senescent cells has been suggested to contribute to
shortened overall lifespan (Baker et al., 2016), and
clearance of such cells was able to bring about a delay
in the appearance of ageing phenotypes in ageing mice
(Baker et al., 2011). Other groups have reported in-
creased lifespan, rejuvenation of ageing phenotypes
such as thinning fur and improved kidney function in
old mice that have undergone targeted removal of se-
nescent cells (Baar et al., 2017). Ablation of senescent
glial cells has been demonstrated to lead to a reduction
of Tau-dependent pathology and improve cognitive
Table 4 Comparison of alternative isoforms of selected brain or
senescence genes in senescent and non-senescent astrocytes
Early passage
astrocytes
Late passage
astrocytes
p value
GFAPΑ 0.809 (0.208) 0.062 (0.013) 0.0021
sKLOTHO 1.155 (0.209) 0.498 (0.275) 0.131
mKLOTHO 1.059 (0.122) 0.381 (0.012) 0.005
AQPM23 1.252 (0.459) 1.067 (0.434) 0.784
TAU3 1.044 (0.114) 0.603 (0.043) 0.023
TAU4 1.23 (0.674) 1.542 (0.196) 0.679
PSEN2 1.009 (0.12) 1.921 (0.158) 0.01
CDKN2A-p14ARF 1.043 (0.044) 0.532 (0.048) 0.001
CDKN2A-p16Ink4A 1.061 (0.076) 2.133 (0.127) 0.002
p21a 1.079 (0.085) 1.666 (0.087) 0.009
p21b 1.016 (0.095) 2.041 (0.077) 0.001
TP53 0.974 (0.052) 1.038 (0.082) 0.541
ATM 0.926 (0.097) 0.612 (0.069) 0.057
Values given refer to the mean expression of each splicing factor in
either early or late passage cells. Values in parentheses are the
standard error of the mean. Transcripts demonstrating significant
differences in expression are given in boldface. N = 3 biological
and 3 technical replicates per sample
Fig. 2 The association between isoform expression and cognitive
decline in the InCHIANTI study of ageing. The graph indicates the
associations between peripheral blood expression of alternatively
expressed transcripts of genes with known links with neurodegen-
erative disease or cellular senescence and mild or severe cognitive
decline is given in this figure. Mild decline is denoted by open
circles; severe decline is denoted by closed circles. *p < 0.05. The
null association point is given by the dotted line. Beta coefficients
of association are given on the X axis and transcript identity is
given on the Y axis. Data are from 197 participants classified as
either mild cognitive decline (a reduction of 2–8 points in MMSE
performance over a 3–7-year period) or severe decline (a reduction
of 9–22 points in MMSE performance over the same period).
Statistical differences in transcript expression between mild and
severe decline are also given
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function in mice (Bussian et al., 2018). Accordingly, we
observe the generation of a strong SASP in astrocytes
that have undergone replicative senescence, which may
be contributory to the inflammatory increases evident in
the pathophysiology of neurodegeneration. The SASP
profile exhibited by the primary human astrocytes does
not match that profile seen in other cell lines from our
previous work (Latorre et al., 2017, Latorre et al.,
2018b, Latorre et al., 2018c); however, cell type speci-
ficity in SASP has previously been described (Coppe
et al., 2010). The reasons behind these variations are
unclear, but may reflect histologically discrete
programmes, dysregulation patterns specific to existing
transcriptomic profiles, or simply arbitrary patterns of
cytokine production which represent the stochastic mo-
lecular dysregulation which is occurring. Our observa-
tions, together with the marked changes in splicing
factor expression, are suggestive that the intersection
between disrupted regulation of splicing, cellular senes-
cence, and its associated inflammatory phenotype in
astrocytes may contribute to astrocyte dysfunction and
have some bearing on eventual cognitive decline. Sim-
ilar changes may also be occurring in other important
proliferative brain cell types such as microglia.
The changes in astrocyte splicing factor expression
we have identified here probably do not act directly on
splicing regulation in blood, but rather reflect related
cognition-associated changes to splicing factor expres-
sion in blood as we have recently described (Lee et al.,
2019). Similarly, the altered expression of alternatively
expressed transcripts in blood may be reflective of sim-
ilar changes that we demonstrate here also occur in
astrocytes. We identified positive associations between
CDKN2A (p14ARF) and TAU3 expression in peripheral
blood and mild cognitive decline, and a negative corre-
lation between GFAPα expression and mild cognitive
decline. The associations between GFAPΑ and
CDKN2A (p14ARF) were not apparent in severe cogni-
tive decline, although this may reflect low power im-
posed by the inherent variability of human biological
samples, since p14 expression in severe decline is
trending in the same direction. The association of
TAU3 expression with severe cognitive decline was still
evident, but was negatively, rather than positively cor-
related. GFAPα expression also demonstrates opposing
direction of effect between mild and severe decline. This
may represent differences in cell subtype populations, or
altered cell characteristics between disease states.
GFAPα, which along with other intermediate filamentsTa
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forms the cytoskeleton, is important for signal transduc-
tion and structural properties (Thomsen et al., 2013).
GFAPα is highly expressed during key developmental
stages during gestation and has also been observed to
have elevated expression levels in brain damage and a
range of neurological diseases (Thomsen et al., 2013).
Some studies have reported no change in whole blood
GFAPα protein levels and hypothesised that without
rapid astroglial destruction, GFAPα levels may not climb
to a detectable level and thus may not be a good indicator
of neurological pathology (Mayer et al., 2013). Such
studies however may not detect changes at the level of
isoforms, if appropriate antibodies capable of specifically
identifying individual splice variants are not used.
Increased levels ofCDKN2A (p14ARF) may be reflec-
tive of an increased load of senescent cells, and is one of
two proteins produced by alternate reading frame of the
CDKN2A locus (Aram et al., 2016). p14ARF inhibits the
activity of MDM2, a protein which sequesters the p53
protein (Wei et al., 2001). Once p53 stabilises and
accumulates, it can trigger DNA repair or the apoptosis
program of cell death (Fridman and Lowe, 2003). The
consequences of increased p14ARF levels are complex
and in places conflicted. It has been demonstrated to
induce either cellular senescence or apoptosis in a p53-
dependant manner (Aram et al., 2016). There have also
been some reports that although CDKN2A (p14ARF)
transcripts are upregulated in senescent cells, TP53
and MDM2 levels can remain unchanged (Wei et al.,
2001). Ectopic expression of p14ARF is capable of in-
ducing senescence but overexpression must be main-
tained to commit cells to a senescent state (Tokarsky-
Amiel et al., 2013). TAU3 transcript expression in the
blood was observed to be correlated positively with mild
cognitive decline, but interestingly, negatively correlat-
ed with severe cognitive decline. Microtubule-
associated protein Tau (MAPT) is an alternatively
spliced regulator of microtubule dynamics—which is
essential for cellular functions from structure to trans-
port (Morris et al., 2011). An ever-growing body of
research in human and animal models of tauopathies is
demonstrating that the delicately balanced 2:1 3R/4R
TAU ratio (Chen et al., 2010), which is achieved
through alternative splicing of exon 10, is imperative
for maintaining healthy function in cells in the brain,
and shifts to disrupt this balance in either direction can
be catastrophic (Schoch et al., 2016, Espindola et al.,
2018, Avale et al., 2013, Chen et al., 2010). A number of
neurodegenerative diseases, including Alzheimer’s and
frontotemporal dementia (FTD), have had tau isoform
balance (specifically 3R and 4R isoforms) implicated in
their pathophysiology (Jakes et al., 1991, Lacovich
et al., 2017, Morris et al., 2011). These include those
examples with premature cognitive decline (Hu et al.,
2007). The precise mechanisms bywhich TAU isoforms
specifically contribute to each neurological pathology
are still being investigated. The directionality of associ-
ation between TAU3 transcript levels and mild and
severe decline is consistent with existing literature sug-
gesting imbalances in 3R/4R isoform ratios, rather than
absolute isoform levels per se, are identified in cases of
dementia and examples of neurodegenerative disease
(Chen et al., 2010, Iqbal et al., 2010).
Our finding of dysregulated splicing factor expression
in human primary astrocytes is novel and consistent with
reports from senescent cells of other tissue types (Holly
et al., 2013, Latorre et al., 2017, Latorre et al., 2018b,
Latorre et al., 2018c). Our study benefits from a system-
atic cells-to-populations approach including primary hu-
man cell lines and an exquisitely characterised longitudi-
nal population study. Weaknesses of this study are the
initial assessment in isolated astrocytes, which may not
represent the holistic nature of the cytological and molec-
ular mechanisms involved in cognitive decline and may
not capture the extent of cross talk between other cell
types in the human brain. It also need to be recognised
that the astrocytes used in this study derive from a single
donor, and that differences reported here would benefit
from confirmation in individuals of different genetic
background. Cell lines from a wider variety of donors
may return more genes of interest; however, these tissues
are rare and difficult to acquire. In addition, our priori list
of genes does not include many other isoforms and genes
involved in the process. Several of the isoforms selected
for study are also not strictly specific for astrocytes. This
is particularly true of the senescence genes tested, which
reflect players in a more global mechanism. Our scope
was narrowed by the need for these genes to be expressed
in the blood, for assessment of association with living
population. Further work may benefit from the whole
transcriptome sequencing and transcriptional profiling
in a number of different cell types.
Our data are consistent with a model by which accu-
mulation of senescent astrocytes (and doubtless other
important brain cell subtypes), their associated disrupted
splicing patterns, and the increased inflammatory micro-
environment may contribute to premature cognitive de-
cline. Inflammation and related cellular stresses are
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capable of activating cell signalling pathways and lead
to further dysregulation of splicing factor expression
(Latorre et al., 2018a), so it is possible that an auto-
regulated feedback loop involving SASP-derived in-
creases in inflammation, dysregulated splicing regula-
tion, and subsequent further increases in senescent cell
loadmay occur as a result of positive feedback. The idea
that some of the features of cognitive decline could
therefore arise from dysregulated splicing of genes im-
portant in the support cells of the brain requires further
exploration. This could be explored further by the se-
lective manipulation of specific isoform levels, followed
by assessment of effects on astrocyte cell kinetics or
astrocyte function in cells and in systems. Our observa-
tions suggest that the role of splicing factor expression
and dysregulated alternative splicing in cognitive de-
cline may represent an interesting line of future
investigation.
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